Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

000,000 shares authorized; 28,837,290 shares issued and

outstanding 288,372

Additional paid-in capital 100,969,362

Deficit accumulated during the development stage (60,199,556)

Total stockholders' equity 41,058,178

Total liabilities and stock and stockholders' equity $45,596,059

MEDIVATION, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS

Inception

Year ended December 31, (September 4, 2003)

2007 2006 to December 31, 2007

Operating expenses:

General and administrative:

Payroll * $2,819,931 $937,677 $4,647,224

Consulting and other

professional fees * 4,086,689 1,964,819 7,952,822

Other general and

administrative 2,222,262 911,638 4,251,064

Total general and

administrative 9,128,882 3,814,134 16,851,110

Research and development:

Payroll * 5,321,212 1,358,735 7,693,780

Consulting and other

professional fees * 3,869,029 2,306,660 8,316,550

Preclinical and clinical

studies 14,088,491 8,405,044 26,658,806

Other research and

development 1,355,332 261,520 1,981,103

Total research and

development 24,634,064 12,331,959 44,650,239

Total operating expenses 33,762,946 16,146,093 61,501,349

Loss from operations (33,762,946
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Commence the Marketing ... Oncology Market, BASKING RIDGE, N.J., March 28 ... Inc. (MBTG) announced today that it has received an,$88,000 ... recently,announced distribution agreement with Ferring, Inc. of Canada. Ferring,Inc. ...
... TVM Capital Joins Investor Syndicate, VIENNA, ... company developing novel antibodies and antibody fragments,based ... today that it,has acquired future royalty obligations ... payment., Modular Antibody Technology was originally ...
... /PRNewswire/ -. Actavis Group, the,international generic pharmaceuticals ... separate approvals from the U.S. Food & ... (SR). Distribution,of the products will commence immediately., ... in,150mg strength, are the generic equivalent of ...
Cached Biology Technology:Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract 2Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract 3Antibody Engineering Company F-Star Buys Back Royalty Obligations 2Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S. 2
(Date:4/18/2014)... that sprout as soon as they,re planted may be good ... more careful. In the wild, a plant whose seeds sprouted ... disaster. More than just an insurance policy against late frosts ... has long-term advantages too: Plants whose seeds put off ... species, finds in a team of researchers working at the ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... more than a dozen scientists from the U.S. Forest ... universities and Region 5 Ecology Program recently released a ... managers as they revise plans for the national forests ... The three most southern national forests in the Sierra ...
... new study from the University of Colorado Denver shows that ... some graves lavish and ornate while the vast majority were ... burials were so ornate, but what,s striking is that they ... 10,000 years," said Julien Riel-Salvatore, Ph.D., assistant professor of anthropology ...
... , , , , , , ... , , AUDIO: ... , Click here for more information. , ... , , , , ...
Cached Biology News:Science synthesis to help guide land management of nation's forests 2Early human burials varied widely but most were simple 2Early human burials varied widely but most were simple 3Low-pitched song indicates fairy-wren size 2Low-pitched song indicates fairy-wren size 3
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... [HDAC8-48] to HDAC8 Regulation of ... mechanisms such as DNA methylation, ATP-dependent ... of histones, which include the dynamic ... of lysine residues present in the ...
... 2-D Sample Preparation for Membrane Proteins ... process 25 membrane,protein extracts for 2-D gel ... Membrane Protein Extraction Kit , ... pellet,fractions with a packed cell weight of ...
...
Biology Products: